当前位置: 首页 > 医学版 > 期刊论文 > 医疗保健 > 《饮食保健》 > 《医食参考》 > 2013年 > 第8期
编号:12819219
DcR3基因在肺癌组织中的表达及临床意义(2)
http://www.100md.com 2013年8月1日 医食参考
     参考文献:

    1.BynleKJ,CoxqSwinsonD.Towardstagemodel for perabel non-small LungCaneer,2001:34:583-89

    2 Shi G, Wu Y, Zhang J. Death decoy receptor TR6/DcR3 inhibitsT-cell chemotaxis in vitro and in vivo. J Immunol. 2003 Oct1,171(7):3407-14.

    3 Hosoe, S.,Kawaguchi, T.; Naka, Y.; Genomic amplificationof a decoy receptor for Fas ligand (DcR3) in lung cancers at various clinical stages,Lung Cancer Volume: 29, Issue: 1,Supplement 1, September, 2000, 196.

    4 Hwang SL, Lin CL, Cheng .Serum concentration of soluble decay receptor 3 in glioma patients before and after surgery. Kaohsiung J Med Sci. 2004 Mar,20(3):124-7.

    5. Shi G, Mao J, Yu G. Tumor Vaccine Based on Cell Surface Expression of DcR3/TR6. J Immunol. 2005 Apr 15,174(8):4727-35.

    6. Fujita Y, Sakakura C, Shimomura K. Chromosome arm 20qgains and other genomic alterations in esophageal squamous cell C arcinoma, as analyzed by comparative genomic hybridization and

    fluorescence in situ hybridization. Hepatogastroenterology. 2003 Nov-Dec,50(54):1857-63., http://www.100md.com(陶国栋 孙明蓓)
上一页1 2